The High Court has temporarily stopped pharmacy group iDexis from manufacturing, supplying and marketing weight-loss medicines containing semaglutide. The iDexis semaglutide ban follows an application by Danish pharmaceutical company Novo Nordisk. The company manufactures Ozempic and Wegovy. Semaglutide is the active ingredient in both medicines. Ozempic is registered as a treatment for diabetes. Wegovy is approved for weight management. The…